A new tool to confront lung cancer

Only 15% of patients with squamous cell lung cancer -- the second most common lung cancer -- survive five years past diagnosis. Little is understood about how the deadly disease arises, preventing development of targeted therapies that could serve as a second line of defense once standard chemotherapy regimens fail.